TX
|
75-2533518
|
(State
or other jurisdiction of
incorporation or organization)
|
(I.R.S.
Employer Identification
No.)
|
8080
N. Central Expressway, Suite
210, LB-59, Dallas, TX
|
75206
|
(Address
of principal executive
offices)
|
(Zip
Code)
|
Page
Number
|
||
PART
I. FINANCIAL INFORMATION
|
||
Item
1.
|
Financial
Statements (Unaudited)
|
3
|
|
||
Statements
of Assets and Liabilities as of March 31, 2005 and December 31,
2004
|
3
|
|
|
||
Schedules
of Investments as of March 31, 2005 and December 31, 2004
|
4
|
|
|
||
Statements
of Operations for the three months ended March 31, 2005 and
2004
|
16
|
|
|
||
Statements
of Changes in Net Assets for the three months ended March 31, 2005
and
2004
|
17
|
|
|
|
|
Statements
of Cash Flows for the three months ended March 31, 2005 and
2004
|
18
|
|
|
||
Notes
to Financial Statements
|
19
|
|
|
||
Item
2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
26
|
|
||
Item
3.
|
Quantitative
and Qualitative Disclosures About Market Risk
|
29
|
|
||
Item
4.
|
Controls
and Procedures
|
29
|
|
||
|
||
|
||
PART
II. OTHER INFORMATION
|
|
|
|
||
Item
1.
|
Legal
Proceedings
|
30
|
|
||
Item
1A.
|
Risk
Factors
|
30
|
|
||
Item
2.
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
33
|
|
||
Item
3.
|
Defaults
Upon Senior Securities
|
33
|
|
||
Item
4.
|
Submission
of Matters to a Vote of Security Holders
|
33
|
|
||
Item
5.
|
Other
Information
|
33
|
|
||
Item
6.
|
Exhibits
|
33
|
March
31,
2005
|
December
31,
2004
|
||||||
|
|||||||
Cash
and cash equivalents
|
$
|
24,962,028
|
$
|
37,278,871
|
|||
Investments
at fair value, cost of $36,062,057 and $38,096,399
at
March 31, 2005 and December 31, 2004, respectively
|
56,908,970
|
76,203,302
|
|||||
Accounts
receivable - settlement with affiliate
|
3,775,872
|
3,775,872
|
|||||
Interest
and dividends receivable
|
106,169
|
95,689
|
|||||
Prepaid
and other assets
|
92,796
|
33,375
|
|||||
$
|
85,845,835
|
$
|
117,387,109
|
||||
|
|||||||
LIABILITIES
AND NET ASSETS
|
|||||||
|
|||||||
Liabilities:
|
|
||||||
Due
to broker
|
$
|
19,992,670
|
$
|
27,001,414
|
|||
Accounts
payable
|
96,896
|
51,477
|
|||||
Accounts
payable - affiliate
|
3,562,507
|
3,697,461
|
|||||
Accounts
payable - dividends
|
—
|
12,054,258
|
|||||
23,652,073
|
42,804,610
|
||||||
Commitments
and contingencies
|
|
||||||
|
|||||||
Net
assets:
|
|
||||||
Common
stock, $1 par value; authorized 20,000,000 shares; 4,673,867
and
4,561,618 issued; 4,463,967 and 4,351,718 shares
outstanding
|
4,673,867
|
4,561,618
|
|||||
Additional
paid-in-capital
|
34,754,220
|
33,641,903
|
|||||
Treasury
stock at cost, 209,900 shares
|
(1,734,967
|
)
|
(1,734,967
|
)
|
|||
Distributable
earnings
|
3,653,729
|
7,042
|
|||||
Net
unrealized appreciation of investments
|
20,846,913
|
38,106,903
|
|||||
|
|||||||
Net
assets, equivalent to $13.93 and $17.14 per share at March 31,
2005
and
December 31, 2004, respectively
|
62,193,762
|
74,582,499
|
|||||
$
|
85,845,835
|
$
|
117,387,109
|
March
31, 2005
|
||||||||||||||||
Interest
Rate
|
Due
Date
|
Cost
|
Fair
Value
|
%
of Net
Investments
|
||||||||||||
Eligible
Portfolio Investments -
Convertible
Debentures and
Promissory
Notes
|
||||||||||||||||
CaminoSoft
Corp.
Promissory
notes (4)
|
7.00
|
%
|
07/19/06
|
$
|
250,000
|
$
|
250,000
|
|
0.44
|
%
|
||||||
Digital
Learning Management Corp. -
Convertible
debenture (2)
|
7.00
|
02/27/11
|
1,000,000
|
167,785
|
0.29
|
|||||||||||
Hemobiotech,
Inc. -
|
||||||||||||||||
Promissory
note (2)
|
10.00
|
10/27/05
|
250,000
|
250,000
|
0.44
|
|||||||||||
iLinc
Communications, Inc. -
Convertible
redeemable note (2)
|
12.00
|
03/29/12
|
500,000
|
500,000
|
0.88
|
|||||||||||
Integrated
Security Systems, Inc. -
|
||||||||||||||||
Promissory
notes (4)
|
8.00
|
09/30/05
|
525,000
|
525,000
|
0.92
|
|||||||||||
Promissory
notes (4)
|
7.00
|
09/30/05
|
200,000
|
200,000
|
0.35
|
|||||||||||
Simtek
Corporation -
Convertible
debenture
|
7.50
|
06/28/09
|
1,000,000
|
1,794,872
|
3.15
|
|||||||||||
$
|
3,725,000
|
$
|
3,687,657
|
6.47
|
%
|
March
31, 2005
|
||||||||||||||||
Interest
Rate
|
Due
Date
|
Cost
|
Fair
Value
|
%
of Net
Investments
|
||||||||||||
Other
Portfolio Investments -
|
||||||||||||||||
Convertible
Debentures and Promissory Notes
|
||||||||||||||||
Advanced
Refractive Technologies (formerly VisiJet, Inc.)
|
||||||||||||||||
Convertible
debenture (2)
|
8.00
|
%
|
01/14/2015
|
$
|
500,000
|
$
|
557,143
|
0.98
|
%
|
|||||||
$
|
500,000
|
$
|
557,143
|
0.98
|
%
|
March
31, 2005
|
|||||||||||||
Shares
|
Cost
|
Fair
Value
|
%
of Net
Investments
|
||||||||||
Eligible
Portfolio Investments -
Common
Stock, Preferred Stock,
and
Miscellaneous Securities
|
|||||||||||||
CaminoSoft
Corp. -
|
|||||||||||||
Common
stock
|
1,750,000
|
$
|
4,000,000
|
$
|
735,000
|
1.29
|
%
|
||||||
Common
stock (2)
|
1,539,414
|
1,150,000
|
646,554
|
1.14
|
|||||||||
Common
stock (2)
|
250,000
|
125,000
|
105,000
|
0.18
|
|||||||||
eOriginal,
Inc. -
|
|||||||||||||
Series
A, preferred stock (1)(3)
|
10,680
|
4,692,207
|
387,671
|
0.68
|
|||||||||
Series
B, preferred stock (1)(3)
|
25,646
|
620,329
|
1,052,420
|
1.85
|
|||||||||
Series
C, preferred stock (1)(3)
|
51,249
|
1,059,734
|
1,391,463
|
2.45
|
|||||||||
Series
D, preferred stock (1)(3)
|
16,057
|
500,000
|
500,000
|
0.88
|
|||||||||
Gaming
& Entertainment Group, Inc.-
Common
stock
|
612,500
|
550,625
|
245,000
|
0.43
|
|||||||||
Gasco
Energy, Inc. - Common stock
|
1,541,667
|
1,250,000
|
4,671,251
|
8.21
|
|||||||||
Global
Axcess Corporation - Common stock (2)
|
4,766,667
|
1,261,667
|
1,525,333
|
2.68
|
|||||||||
Hemobiotech,
Inc. - Common stock (2)
|
294,120
|
250,000
|
250,000
|
0.44
|
|||||||||
Integrated
Security Systems, Inc. -
|
|||||||||||||
Common
stock (2)
|
27,074,179
|
5,568,058
|
9,205,221
|
16.18
|
|||||||||
Series
D, preferred stock (2)
|
187,500
|
150,000
|
76,500
|
0.13
|
March
31, 2005
|
|||||||||||||
Shares
|
Cost
|
Fair
Value
|
%
of Net
Investments
|
||||||||||
Eligible
Portfolio Investments -
Common
Stock, Preferred Stock,
and
Miscellaneous Securities, continued
|
|||||||||||||
Inyx,
Inc. - Common stock (2)
|
300,000
|
300,000
|
309,000
|
0.54
|
|||||||||
Laserscope
- Common stock
|
600,000
|
750,000
|
19,044,000
|
33.47
|
|||||||||
Poore
Brothers, Inc. - Common stock (2)
|
46,027
|
38,835
|
142,223
|
0.25
|
|||||||||
PracticeXpert,
Inc. - Common stock (2)
|
4,166,666
|
500,000
|
300,000
|
0.53
|
|||||||||
Simtek
Corp. -
|
|||||||||||||
Common
stock
|
1,000,000
|
195,000
|
560,000
|
0.98
|
|||||||||
Common
stock - private placement (2)
|
550,661
|
500,000
|
308,370
|
0.54
|
|||||||||
Tarantella,
Inc. - Common stock (2)
|
714,286
|
1,000,000
|
857,143
|
1.51
|
|||||||||
ThermoView
Industries, Inc. - Common stock
|
234,951
|
563,060
|
82,233
|
0.14
|
|||||||||
Miscellaneous
Securities
|
—
|
1,288,680
|
2.26
|
||||||||||
$
|
25,024,515
|
$
|
43,683,062
|
76.76
|
%
|
March
31, 2005
|
|||||||||||||
Shares
|
Cost
|
Fair
Value
|
%
of Net
Investments
|
||||||||||
Other
Portfolio Investments -
Common
Stock, Preferred Stock,
and
Miscellaneous Securities
|
|||||||||||||
AdStar,
Inc. - Common stock (2)
|
269,231
|
$
|
350,000
|
$
|
220,769
|
0.39
|
%
|
||||||
Advance
Nanotech, Inc. - Common stock (2)
|
165,000
|
330,000
|
1,196,250
|
2.10
|
|||||||||
Bovie
Medical Corporation - Common stock (2)
|
300,000
|
525,000
|
705,000
|
1.24
|
|||||||||
Comtech
Group, Inc. - Common stock (2)
|
240,000
|
840,000
|
1,440,000
|
2.53
|
|||||||||
Cybex
International - Common stock (2)
|
145,000
|
478,500
|
584,350
|
1.03
|
|||||||||
iLinc
Communications, Inc.- Common stock
|
48,266
|
27,033
|
17,859
|
0.03
|
|||||||||
Gasco
Energy, Inc. - Common stock
|
750,000
|
639,105
|
2,272,500
|
3.99
|
|||||||||
i2
Telecom - Convertible Preferred (2)
|
625
|
618,750
|
581,250
|
1.02
|
|||||||||
Medical
Action Industries, Inc. - Common stock
|
20,100
|
237,209
|
379,890
|
0.67
|
|||||||||
PhotoMedex,
Inc. - Common stock
|
70,000
|
176,400
|
188,300
|
0.33
|
|||||||||
Precis,
Inc. - Common stock
|
200,700
|
1,372,417
|
340,387
|
0.60
|
March
31, 2005
|
|||||||||||||
Shares
|
Cost
|
Fair
Value
|
%
of Net
Investments
|
||||||||||
Other
Portfolio Investments -
Common
Stock, Preferred Stock,
and
Miscellaneous Securities, continued
|
|||||||||||||
Stonepath
Group, Inc. - Common stock
|
131,240
|
246,000
|
141,739
|
0.25
|
|||||||||
Tarantella,
Inc. - Common stock
|
202,762
|
186,541
|
243,314
|
0.43
|
|||||||||
US
Home Systems, Inc. - Common stock
|
110,000
|
535,587
|
572,000
|
1.01
|
|||||||||
Vaso
Active Pharmaceuticals, Inc. - Common stock
|
150,000
|
250,000
|
97,500
|
0.17
|
|||||||||
6,812,542
|
8,981,108
|
15.79
|
%
|
||||||||||
$
|
36,062,057
|
$
|
56,908,970
|
100.00
|
%
|
||||||||
Allocation
of Investments -
Restricted
Shares, Unrestricted Shares,
and
Other Securities
|
|||||||||||||
Restricted
Securities (2)
|
$
|
16,235,810
|
$
|
19,927,891
|
35.02
|
%
|
|||||||
Unrestricted
Securities
|
$
|
11,978,977
|
$
|
31,385,845
|
55.15
|
%
|
|||||||
Other
Securities (5)
|
$
|
7,847,270
|
$
|
5,595,234
|
9.83
|
%
|
(1) |
Valued
at fair value as determined by the Investment Adviser (Note
6).
|
(2) |
Restricted
securities - securities that are not fully registered and freely
tradable.
|
(3) |
Securities
in a privately owned company.
|
(4) |
Securities
that have no provision allowing conversion into a security for which
there
is a public market.
|
(5)
|
Includes
Miscellaneous Securities, securities of privately owned companies,
securities with no conversion feature, and securities for which there
is
no market.
|
December
31, 2004
|
||||||||||||||||
Interest
Rate
|
Due
Date
|
Cost
|
Fair
Value
|
%
of Net
Investments
|
||||||||||||
Eligible
Portfolio Investments -
Convertible
Debentures and
Promissory
Notes
|
||||||||||||||||
CaminoSoft
Corp. -
Promissory
note (4)
|
7.00
|
%
|
07/19/06
|
$
|
250,000
|
$
|
250,000
|
0.33
|
%
|
|||||||
Digital
Learning, Inc. -
Convertible
debenture (2)
|
7.00
|
02/27/11
|
1,000,000
|
1,342,282
|
1.76
|
|||||||||||
Hemobiotech,
Inc. -
Promissory
note (2)
|
10.00
|
10/27/05
|
250,000
|
250,000
|
0.33
|
|||||||||||
iLinc
Communications, Inc. -
Convertible
promissory note (2)
|
12.00
|
03/29/12
|
500,000
|
500,000
|
0.66
|
|||||||||||
Integrated
Security Systems, Inc. -
|
||||||||||||||||
Promissory
note (4)
|
8.00
|
09/30/05
|
525,000
|
525,000
|
0.69
|
|||||||||||
Promissory
note (4)
|
7.00
|
09/30/05
|
200,000
|
200,000
|
0.26
|
|||||||||||
Simtek
Corporation -
Convertible
debenture (2)
|
7.50
|
06/28/09
|
1,000,000
|
1,923,077
|
2.52
|
|||||||||||
$
|
3,725,000
|
$
|
4,990,359
|
6.55
|
%
|
|
December
31, 2004
|
|||||||||||||||
Interest
Rate
|
Due
Date
|
Cost
|
Fair
Value
|
%
of Net
Investments
|
||||||||||||
Other
Portfolio Investments -
Convertible
Debentures and
Promissory
Notes
|
||||||||||||||||
Interpool,
Inc. -
Convertible
debenture (2)
|
9.25
|
12/27/22
|
$
|
375,000
|
$
|
375,000
|
0.49
|
%
|
||||||||
$
|
375,000
|
$
|
375,000
|
0.49
|
%
|
December
31, 2004
|
|||||||||||||
Shares
|
Cost
|
Fair
Value
|
%
of Net
Investments
|
||||||||||
Eligible
Portfolio Investments -
Common
Stock, Preferred Stock,
and
Miscellaneous Securities
|
|||||||||||||
CaminoSoft
Corp. -
|
|||||||||||||
Common
stock
|
2,458,333
|
$
|
4,875,000
|
$
|
1,696,250
|
2.23
|
%
|
||||||
Common
stock (2)
|
1,081,081
|
400,000
|
745,946
|
0.98
|
|||||||||
eOriginal,
Inc. -
|
|||||||||||||
Series
A, preferred stock (1)(3)
|
10,680
|
4,692,207
|
332,575
|
0.44
|
|||||||||
Series
B, preferred stock (1)(3)
|
25,646
|
620,329
|
798,616
|
1.05
|
|||||||||
Series
C, preferred stock (1)(3)
|
51,249
|
1,059,734
|
1,595,894
|
2.09
|
|||||||||
Series
D, preferred stock (1)(3)
|
16,057
|
500,000
|
500,015
|
0.66
|
|||||||||
Gaming
& Entertainment Group -
Common
stock (2)
|
500,000
|
500,000
|
210,000
|
0.28
|
|||||||||
Gasco
Energy, Inc. -
Common
stock (2)
|
1,541,667
|
1,250,000
|
6,567,501
|
8.62
|
|||||||||
Global
Axcess Corporation -
Common
stock (2)
|
4,766,667
|
1,261,667
|
1,716,000
|
2.25
|
|||||||||
Hemobiotech,
Inc. -
Common
stock (2)
|
294,120
|
250,000
|
250,000
|
0.33
|
|||||||||
Integrated
Security Systems, Inc. -
|
|||||||||||||
Common
stock (2)
|
27,074,179
|
5,568,056
|
13,537,090
|
17.76
|
|||||||||
Series
D, preferred stock (2)
|
187,500
|
150,000
|
112,500
|
0.15
|
December
31, 2004
|
|||||||||||||
Shares
|
Cost
|
Fair
Value
|
%
of Net
Investments
|
||||||||||
Eligible
Portfolio Investments -
Common
Stock, Preferred Stock,
and
Miscellaneous Securities, continued
|
|||||||||||||
Inyx,
Inc. - Common stock (2)
|
300,000
|
300,000
|
417,000
|
0.55
|
|||||||||
Laserscope
- Common stock
|
600,000
|
750,000
|
21,546,000
|
28.27
|
|||||||||
Poore
Brothers, Inc. -
Common
stock (2)
|
1,507,791
|
1,544,294
|
5,262,191
|
6.91
|
|||||||||
PracticeXpert,
Inc. -
Common
stock (2)
|
4,166,666
|
500,000
|
562,500
|
0.74
|
|||||||||
Simtek
Corp. -
|
|||||||||||||
Common
stock (2)
|
550,661
|
500,000
|
330,397
|
0.43
|
|||||||||
Common
stock
|
1,000,000
|
195,000
|
600,000
|
0.79
|
|||||||||
Tarantella,
Inc. -
Common
stock (2)
|
714,286
|
1,000,000
|
1,200,000
|
1.57
|
|||||||||
ThermoView
Industries, Inc. -
Common
stock
|
234,951
|
563,060
|
122,175
|
0.16
|
|||||||||
Miscellaneous
Securities
|
—
|
1,051,436
|
1.38
|
||||||||||
$
|
26,479,347
|
$
|
59,154,086
|
77.63
|
%
|
December
31, 2004
|
|||||||||||||
Shares
|
Cost
|
Fair
Value
|
%
of Net
Investments
|
||||||||||
Other
Portfolio Investments -
Common
Stock, Preferred Stock,
and
Miscellaneous Securities
|
|||||||||||||
AdStar,
Inc. - Common stock (2)
|
269,231
|
$
|
350,000
|
$
|
293,462
|
0.39
|
%
|
||||||
Bovie
Medical Corporation -
Common
stock (2)
|
300,000
|
525,000
|
762,000
|
1.00
|
|||||||||
Comtech
Group, Inc. -
Common
stock (2)
|
480,000
|
840,000
|
1,435,200
|
1.88
|
|||||||||
Cybex
International -
Common
stock (2)
|
145,000
|
478,500
|
593,050
|
0.78
|
|||||||||
Dave
& Busters, Inc. -
Common
stock
|
100,000
|
653,259
|
2,020,000
|
2.65
|
|||||||||
iLinc
Communications, Inc. (formerly EDT Learning, Inc.) -
Common
stock
|
48,266
|
27,033
|
22,685
|
0.03
|
|||||||||
Gasco
Energy, Inc. -
Common
stock
|
750,000
|
639,105
|
3,195,000
|
4.19
|
|||||||||
i2
Telecom -
Convertible
preferred stock (2)
|
500
|
500,000
|
500,000
|
0.66
|
|||||||||
Intrusion,
Inc. -
Convertible
preferred stock (2)
|
100,000
|
500,000
|
500,000
|
0.66
|
|||||||||
Medical
Action Industries, Inc. -
Common
stock
|
20,100
|
237,209
|
395,970
|
0.52
|
|||||||||
PhotoMedex,
Inc. -
Common
stock
|
70,000
|
176,400
|
189,000
|
0.25
|
December
31, 2004
|
|||||||||||||
Shares
|
Cost
|
Fair
Value
|
%
of Net
Investments
|
||||||||||
Other
Portfolio Investments -
Common
Stock, Preferred Stock,
and
Miscellaneous Securities, continued
|
|||||||||||||
Precis,
Inc. -
Common
stock
|
200,700
|
1,372,417
|
533,862
|
0.70
|
|||||||||
Stonepath
Group, Inc. - Common stock
|
131,240
|
246,000
|
157,488
|
0.21
|
|||||||||
Tarantella,
Inc. -
Common
stock
|
202,762
|
186,541
|
340,640
|
0.45
|
|||||||||
US
Home Systems, Inc. -
Common
stock
|
110,000
|
535,587
|
676,500
|
0.89
|
|||||||||
Vaso
Active Pharmaceuticals, Inc. -
Common
stock
|
150,000
|
250,000
|
69,000
|
0.09
|
|||||||||
7,517,051
|
11,683,857
|
15.33
|
|||||||||||
$
|
38,096,398
|
$
|
76,203,302
|
100.00
|
%
|
||||||||
Allocation
of Investments -
Restricted
Shares, Unrestricted Shares,
and
Other Securities
|
|||||||||||||
Restricted
Securities (2)
|
$
|
19,542,517
|
$
|
39,385,196
|
51.69
|
%
|
|||||||
Unrestricted
Securities
|
$
|
10,706,611
|
$
|
31,564,570
|
41.42
|
%
|
|||||||
Other
Securities (5)
|
$
|
7,847,270
|
$
|
5,253,536
|
6.89
|
%
|
(1) |
Valued
at fair value as determined by the Investment Adviser (Note
6).
|
(2) |
Restricted
securities - securities that are not fully registered and freely
tradable.
|
(3) |
Securities
in a privately owned company.
|
(4) |
Securities
that have no provision allowing conversion into a security for which
there
is a public market.
|
(5)
|
Includes
Miscellaneous Securities, securities of privately owned companies,
securities with no conversion feature, and securities for which there
is
no market.
|
Three
Months Ended March 31,
|
|||||||
2005
|
2004
|
||||||
Income:
|
|||||||
Interest
income
|
$
|
83,888
|
$
|
79,963
|
|||
Dividend
income
|
17,355
|
20,983
|
|||||
Other
income
|
50,625
|
28,282
|
|||||
151,868
|
129,228
|
||||||
Expenses:
|
|||||||
General
and administrative
|
73,662
|
103,364
|
|||||
Interest
expense
|
9,878
|
13,406
|
|||||
Legal
and professional fees
|
131,853
|
129,873
|
|||||
Management
fee to affiliate
|
273,293
|
410,131
|
|||||
488,686
|
656,774
|
||||||
Net
investment loss
|
(336,818
|
)
|
(527,546
|
)
|
|||
Realized
and unrealized gain (loss) on investments:
|
|||||||
Net
change in unrealized appreciation of investments
|
(17,259,989
|
)
|
10,292,651
|
||||
Net
realized gain on investments
|
4,093,083
|
14,163,079
|
|||||
Net
gain (loss) on investments
|
(13,166,906
|
)
|
24,455,730
|
||||
Net
income (loss)
|
$
|
(13,503,724
|
)
|
$
|
23,928,184
|
||
Net
income (loss) per share
|
$
|
(3.06
|
)
|
$
|
5.50
|
||
Weighted
average shares outstanding
|
4,412,831
|
4,351,718
|
Three
Months Ended March 31,
|
|||||||
2005
|
2004
|
||||||
From
operations:
|
|||||||
Net
investment loss
|
$
|
(336,818
|
)
|
$
|
(527,546
|
)
|
|
Net
realized gain on investments
|
4,093,083
|
14,163,079
|
|||||
Net
change in unrealized appreciation on investments
|
(17,259,989
|
)
|
10,292,651
|
||||
Net
income (loss)
|
(13,503,724
|
)
|
23,928,184
|
||||
From
distributions to stockholders:
|
|||||||
Common
stock dividends declared from realized capital gains
|
(446,396
|
)
|
(435,174
|
)
|
|||
From
capital transactions:
|
|||||||
Sale
of common stock
|
1,561,383
|
—
|
|||||
Total
increase (decrease) in net assets
|
(12,388,737
|
)
|
23,493,010
|
||||
Net
assets:
|
|||||||
Beginning
of period
|
74,582,499
|
69,405,964
|
|||||
End
of period
|
$
|
62,193,762
|
$
|
92,898,974
|
Three
Months Ended March 31,
|
|||||||
2005
|
2004
|
||||||
Cash
flows from operating activities:
|
|||||||
Net
income (loss)
|
$
|
(13,503,724
|
)
|
$
|
23,928,184
|
||
Adjustments
to reconcile net income to net cash provided by (used in) operating
activities:
|
|||||||
Net
change in unrealized appreciation on investments
|
17,259,989
|
(10,292,651
|
)
|
||||
Net
realized gain on investments
|
(4,093,083
|
)
|
(14,163,079
|
)
|
|||
(Increase)
decrease in interest and dividends receivable
|
(10,480
|
)
|
176,628
|
||||
Increase
in prepaid and other assets
|
(59,420
|
)
|
(5,828
|
)
|
|||
Increase
in accounts payable
|
45,419
|
63,846
|
|||||
Decrease
in accounts payable-affiliate
|
(134,964
|
)
|
(972,463
|
)
|
|||
Increase
(decrease) in due to broker
|
(7,008,744
|
)
|
3,915
|
||||
Purchase
of investments
|
(995,104
|
)
|
(4,350,738
|
)
|
|||
Proceeds
from sale of investments
|
7,122,539
|
15,814,708
|
|||||
Net
cash provided by (used in) operating activities
|
(1,377,572
|
)
|
10,202,522
|
||||
Cash
flows from financing activities:
|
|||||||
Cash
dividends paid
|
(12,500,654
|
)
|
(4,134,134
|
)
|
|||
Sale
of common stock
|
1,561,383
|
—
|
|||||
Net
cash used in financing activities
|
(10,939,271
|
)
|
(4,134,134
|
)
|
|||
Net
increase (decrease) in cash and cash equivalents
|
(12,316,843
|
)
|
6,068,388
|
||||
Cash
and cash equivalents at beginning of the period
|
37,278,871
|
35,255,687
|
|||||
Cash
and cash equivalents at end of period
|
$
|
24,962,028
|
$
|
41,324,075
|
|||
Cash
paid during the period - interest
|
$
|
9,878
|
$
|
13,406
|
Note 1 - |
Organization
and Business
Purpose
|
Note 2 - |
Summary
of Significant Accounting
Policies
|
Note
2 -
|
Summary
of Significant Accounting Policies,
continued
|
Note 3 - |
Due
to Broker
|
Note 4 - |
Management
and Incentive Fees
|
Note
4 -
|
Management
and Incentive Fees,
continued
|
· |
The
Investment Adviser receives a management fee equal to a quarterly
rate of
0.4375% of the Fund’s net assets, as determined at the end of such quarter
with each such payment to be due as of the last day of the calendar
quarter. The Fund incurred $273,293 and $410,131 for management fees
during the quarters ended March 31, 2005 and 2004,
respectively.
|
· |
The
Investment Adviser receives an incentive fee in an amount equal to
20% of
the Fund’s cumulative realized capital gains in excess of cumulative
realized capital losses of the Fund after allowance for any unrealized
capital depreciation on the portfolio investments of the Fund at
the end
of the period being calculated less cumulative incentive fees previously
accrued. Unrealized capital depreciation equals net unrealized capital
loss on each class of security without netting net unrealized capital
gains on other classes of securities. Because the incentive fee is
calculated, accrued, and paid on an annual basis as of each year
end and
no probability or estimate of the ultimate fee can be ascertained,
no
incentive fee was recorded during the quarters ended March 31, 2005
and
2004.
|
· |
The
Investment Adviser was reimbursed by the Fund for administrative
expenses
paid by the Investment Adviser on behalf of the Fund. Such reimbursements
were $86,139 and $158,281 during the quarters ended March 31, 2005
and
2004, respectively.
|
Note 5 - |
Eligible
Portfolio Companies and
Investments
|
Note
5 -
|
Eligible
Portfolio Companies and Investments,
continued
|
Note 6 - |
Valuation
of Investments
|
· |
The
common stock of companies listed on an exchange, Nasdaq or in the
over-the-counter market is valued at the closing price on the date
of
valuation.
|
· |
The
unlisted preferred stock of companies with common stock listed on
an
exchange, Nasdaq or in the over-the-counter market is valued at the
closing price of the common stock into which the preferred stock
is
convertible on the date of valuation. If the preferred stock is
redeemable, the preferred stock is valued at the greater of cost
or
market.
|
· |
The
unlisted in-the-money options or warrants of companies with the underlying
common stock listed on an exchange, Nasdaq or in the over-the-counter
market are valued at the positive difference between the closing
price of
the underlying common stock and the strike price of the warrant or
option.
An out-of-the money warrant or option has no intrinsic value; thus,
we
assign no value to it.
|
· |
Debt
securities are valued at the greater of (i) cost or (ii) the market
value
of the underlying common stock into which the debt instrument is
convertible. In cases where the debt instrument is in default or
the
company is in bankruptcy, the value will be (i) the value of the
underlying common stock, (ii) the value of the collateral, if secured,
or
(iii) zero, if the common stock has no value and there is no
collateral.
|
Note
6 -
|
Valuation
of Investments,
continued
|
· |
If
there is no independent and objective pricing authority (i.e. a public
market) for investments in privately held entities, the latest sale
of
equity securities to independent third parties by the entity governs
the
value of that enterprise. This valuation method causes the Fund’s initial
investment in the private entity to be valued at cost. Thereafter,
new
issuances or offers of equity or equity-linked securities by the
portfolio
company to new investors will be used to determine enterprise value
as
they will provide the most objective and independent basis for determining
the worth of the issuer. Where a private entity does not have an
independent value established over an extended period of time, then
the
Investment Adviser will determine fair value on the basis of appraisal
procedures established in good faith and approved by the Fund’s Board of
Directors.
|
Note 7 - |
Restricted
Securities
|
Note 8 - |
Distribution
to Shareholders
|
Note 9 - |
Settlement
with the Investment Advisor
|
Note 9
-
|
Settlement
with the Investment Advisor,
continued
|
Note 10 - |
Commitments
and Contingencies
|
Note
11 -
|
Financial
Highlights - unaudited
|
2005
|
2004
|
||||||
Net
asset value, beginning of period
|
$
|
17.14
|
$
|
15.95
|
|||
Effect
of share change
|
(.43
|
)
|
-
|
||||
Net
investment loss
|
(.08
|
)
|
(.12
|
)
|
|||
Net
realized and unrealized gain (loss) on investments
|
(2.95 |
)
|
5.62 | ||||
Total
return from investment operations
|
(3.46
|
)
|
5.50
|
||||
Shares
issued
|
.35
|
.00
|
|||||
Distributions
|
(.10
|
)
|
(.10
|
)
|
|||
Net
asset value, end of period
|
$
|
13.93
|
$
|
21.35
|
|||
Per
share market value, end of period
|
$
|
11.40
|
$
|
17.24
|
|||
Portfolio
turnover rate (quarterly)
|
1.50
|
%
|
6.58
|
%
|
|||
Quarterly
return (a)
|
(11.97
|
)%
|
28.75
|
%
|
|||
Ratio
to average net assets (quarterly) (b):
|
|||||||
Net
investment income (loss)
|
(0.49
|
)%
|
(0.65
|
)%
|
|||
Expenses
|
.72
|
%
|
.81
|
%
|
(a) |
Three
month return (not annualized) was calculated by comparing the common
stock
price on the first day of the period to the common stock price on
the last
day of the period, in accordance with American Institute of Certified
Public Accountants guidelines.
|
(b) |
Average
net assets have been computed based on quarterly
valuations.
|
Item 1. |
Legal
Proceedings
|
Item 1A. |
Risk
Factors
|
Item 2. |
Unregistered
Sales of Equity Securities and Use of
Proceeds
|
Item 3. |
Defaults
Upon Senior Securities
|
Item 4. |
Submission
of Matters to a Vote of Security
Holders
|
Item 5. |
Other
Information
|
Item 6. |
Exhibits
|
31.1
|
Certification
of the principal executive officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
|
31.2
|
Certification
of the principal financial officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
|
32.1
|
Certification
of the principal executive officer pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002
|
32.2
|
Certification
of the principal financial officer pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002
|
/s/ Russell Cleveland | December 19, 2006 | |
Russell
Cleveland, President and
Chief
Executive Officer
(Principal
Executive Officer)
|
||
/s/ Barbe Butschek | December 19, 2006 | |
Barbe
Butschek, Chief Financial Officer
(Principal
Financial Officer)
|